2023 World Conference on Lung Cancer (Posters)-EP11.03. Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC

EP11.03. Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy of adding immune checkpoint inhibitor (ICI) to platinum-based chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). A multi-institutional retrospective analysis was conducted on patients treated with either ICI plus chemotherapy or chemotherapy alone after failure of EGFR tyrosine kinase inhibitors (TKIs). The study included patients from three institutions in Japan. The baseline characteristics of patients in both groups were compared, including age, gender, Eastern Cooperative Oncology Group performance status, stage, histology, PD-L1 expression, EGFR mutation status, prior use of osimertinib, and presence of liver metastases.<br /><br />The results showed that the response rate was higher in the ICI plus chemotherapy group compared to the chemotherapy alone group. However, the addition of ICI to platinum-based chemotherapy did not significantly prolong progression-free survival (PFS) or overall survival (OS) in patients with EGFR-mutated NSCLC. Multivariate analysis revealed that postoperative recurrence was significantly associated with better PFS, and prior use of osimertinib was significantly associated with better OS.<br /><br />In conclusion, this study suggests that the addition of ICI to platinum-based chemotherapy did not improve PFS or OS in patients with EGFR-mutated NSCLC, regardless of the chemotherapy regimen. The findings highlight the need for further research and the identification of alternative treatment strategies for this patient population.

Asset Subtitle

Shunichi Kataoka

Meta Tag

Speaker Shunichi Kataoka

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immune checkpoint inhibitor

platinum-based chemotherapy

epidermal growth factor receptor

non-small cell lung cancer

retrospective analysis

EGFR tyrosine kinase inhibitors

PD-L1 expression

osimertinib

liver metastases

progression-free survival